What is Abzena?
Abzena operates as a leading partner research organization (PRO) within the biopharmaceutical sector, offering end-to-end services that span integrated discovery, development, and cGMP manufacturing for biologics and bioconjugates. The company's value proposition lies in its ability to provide a complete set of solutions, from early discovery through mid-phase development and manufacturing, catering to the complex needs of biotherapeutic and bioconjugation drug development. With facilities strategically located in the US and UK, Abzena supports global biopharmaceutical innovation.
How much funding has Abzena raised?
Abzena has raised a total of $113.6M across 5 funding rounds:
Stock Offering
$34.3M
Unspecified
$700K
Private Equity
$3.6M
Private Equity
$10M
Unspecified
$65M
Stock Issuance/Offering (2014): $34.3M, investors not publicly disclosed
Unspecified (2015): $700K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Private Equity (2020): $10M featuring Biospring Partners
Unspecified (2022): $65M backed by Anderson & Stowe, Carson, and Welsh
Key Investors in Abzena
Welsh, Carson, Anderson & Stowe
Welsh, Carson, Anderson & Stowe is identified as one of the world's leading private equity investors, likely focusing on significant investments in established companies within the healthcare and technology sectors.
Biospring Partners
Biospring Partners is a venture capital firm that appears to specialize in providing capital and strategic support to companies within the life sciences and biotechnology industries.
Undisclosed investor
An undisclosed investor participated in the funding round, indicating a strategic partner whose involvement is not publicly detailed but is significant to the company's financial backing.
What's next for Abzena?
The recent major strategic investment signifies a critical juncture for Abzena, likely enabling accelerated expansion of its service offerings, enhancement of its manufacturing capabilities, and further penetration into key markets. This capital injection, coupled with the company's established expertise in biologics and bioconjugates, suggests a strategic focus on scaling operations and potentially pursuing new technological advancements or therapeutic areas. The company's trajectory indicates a strong emphasis on solidifying its position as a comprehensive partner for biopharmaceutical development and manufacturing.
See full Abzena company page
